Clinical trial · Observational
Evaluation of the Efficacy of Radiofrequency in the Treatment of Renal Tumors
Evaluation of the Efficacy of Radiofrequency Ablation in the Treatment of Renal Tumors: Prospective Observational Study
NCT02850809CI-TRIAL-00066046RF-REINcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Multi-institutional registry on a cohort of 310 patients with biopsy-proven renal cell carcinoma treated by Radiofrequency ablation. All patients will be included consecutively and retrospectively in all centers to obtain the required number of patient followed during 5 years.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- patients
- description
- Treated by percutaneous image-guided radiofrequency for renal tumor
Primary outcomes (1)
- measure
- Rate of local efficacy of RFA treatment
- timeFrame
- 60 months after the RFA treatment (D0)
Secondary outcomes (3)
- measure
- Overall success
- timeFrame
- At 60 months after the RFA treatment (D0)
- measure
- No recurrence of RCC
- timeFrame
- At 60 months after the RFA treatment (D0)
- measure
- Tolerance of the treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient treated with percutaneous RFA * Patient with diagnosis of renal masses with a maximum of 3 masses treated during the ablation * The diameter of the tumor must be ≤ 40 mm, characterized by CT-scan or MRI * The histology of the tumor must be biopsy-proven or the patient must have previous surgical ablation of renal tumor (ipsi or contralateral) Exclusion Criteria: * Patient treated by surgery or laparoscopy * Benign tumors * No histological diagnosis (no biopsy or no previous treated renal carcinoma) * Patient having secondary malignant sites, ganglions or visceral metastatic cells or endo-venous extend at the time of RFA * Patient having a diagnosis of primary or secondary extra-renal tumor location and not into remission * Patients treated with antiangiogenic drugs during the 6 months prior RFA.
References
Publications (0)
Data not yet available
No reference posted for this study.